NGM282(一种FGF19类似物)在原发性硬化性胆管炎中的效果:一项多中心、随机、双盲、安慰剂对照II期试验
这项多中心、随机、双盲、安慰剂对照II期试验纳入62例经胆管造影或活检确诊且碱性磷酸酶(ALP)>1.5倍正常上限的原发性硬化性胆管炎(PSC)患者,按1:1:1随机接受NGM282 1 mg、3 mg或安慰剂每日一次治疗12周。主要终点第12周ALP自基线变化在NGM282组与安慰剂组间无显著差异,主要终点未达到;但NGM282显著降低CYP7A1活性标志物7α-羟基-4-胆甾烯-3-酮和胆汁酸水平,并显著改善增强肝纤维化(ELF)评分和Pro-C3等纤维化生物标志物。
要点
- NGM282 1 mg和3 mg每日一次治疗12周未显著改善PSC患者ALP水平,主要终点未达到。
- NGM282显著降低CYP7A1活性标志物7α-羟基-4-胆甾烯-3-酮和胆汁酸水平。
- NGM282显著改善增强肝纤维化评分和Pro-C3等预测无移植生存的纤维化生物标志物。
核心结论
- 在PSC患者中,NGM282强效抑制胆汁酸合成并降低纤维化标志物,但未显著影响ALP水平。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照II期试验,纳入62例经胆管造影或活检确诊且ALP>1.5倍正常上限的PSC患者,按1:1:1随机接受NGM282 1 mg、3 mg或安慰剂每日一次治疗12周,主要终点为第12周ALP自基线变化,疗效分析采用意向性治疗。
主要发现
- 第12周NGM282组与安慰剂组ALP自基线平均变化无显著差异,主要终点未达到。
- 与安慰剂相比,NGM282 1 mg组7α-羟基-4-胆甾烯-3-酮最小二乘均值差异为-6.2 ng/ml(95%CI -10.7至-1.7;p=0.008),3 mg组为-9.4 ng/ml(95%CI -14.0至-4.9;p<0.001)。
- NGM282显著降低胆汁酸水平,并显著改善增强肝纤维化评分和Pro-C3等纤维化生物标志物。
- 大多数不良事件为轻至中度,胃肠道症状在NGM282治疗组更常见。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Primary sclerosing cholangitis (PSC) is an inflammatory, cholestatic and progressively fibrotic liver disease devoid of effective medical intervention. NGM282, an engineered, non-tumorigenic FGF19 analogue, potently regulates CYP7A1-mediated bile acid homeostasis. We assessed the activity and safety of NGM282 in patients with PSC. METHODS: In this double-blind, placebo-controlled phase II trial, 62 patients who had PSC confirmed by cholangiography or biopsy and an elevated alkaline phosphatase (ALP) >1.5 × the upper limit of normal were randomly assigned 1:1:1 to receive NGM282 1 mg, 3 mg or placebo once daily for 12 weeks. The primary outcome was the change in ALP from baseline to week 12. Secondary and exploratory outcomes included changes in serum biomarkers of bile acid metabolism and fibrosis. Efficacy analysis was by intention-to-treat. RESULTS: At 12 weeks, there were no significant differences in the mean change from baseline in ALP between the NGM282 and placebo groups, and therefore, the primary endpoint was not met. However, NGM282 significantly reduced levels of 7alpha-hydroxy-4-cholesten-3-one (a marker of hepatic CYP7A1 activity, LS mean differences -6.2 ng/ml (95% CI -10.7 to -1.7; p = 0.008) and -9.4 ng/ml (-14.0 to -4.9; p <0.001) in the NGM282 1 mg and 3 mg groups, respectively, compared with placebo) and bile acids. Importantly, fibrosis biomarkers that predict transplant-free survival, including Enhanced Liver Fibrosis score and Pro-C3, were significantly improved following NGM282 treatment. Most adverse events were mild to moderate in severity, with gastrointestinal symptoms more frequent in the NGM282 treatment groups. CONCLUSIONS: In patients with PSC, NGM282 potently inhibited bile acid synthesis and decreased fibrosis markers, without significantly affecting ALP levels. LAY SUMMARY: We present for the first time, the clinical and laboratory effects of a first-in-class, engineered analogue of the endocrine hormone FGF19 in patients with primary sclerosing cholangitis (PSC). By incorporating non-invasive markers of fibrosis, beyond standard liver injury markers, we show that NGM282 impacted on fibrosis turnover and hepatic inflammation without changing alkaline phosphatase. Our findings demonstrate the complexities of using highly potent rational agents in PSC, and furthermore challenge the dogma about what the appropriate endpoints should be for trials in PSC.
引用
- Hirschfield GM, Chazouillères O, Drenth JP, et al. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial. J Hepatol. 2018. PMID: 30414864. doi:10.1016/j.jhep.2018.10.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。